A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/08/2001	WO2001083469A1 Cdk inhibitors having 3-hydroxychromen-4-one structure
11/08/2001	WO2001083465A2 Alkynyl phenyl heteroaromatic glucokinase activators
11/08/2001	WO2001083464A1 Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
11/08/2001	WO2001083462A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments
11/08/2001	WO2001083457A2 Benzimidazole-2-carbamates and their use in cancer treatment
11/08/2001	WO2001083456A1 Condensed heteroaryl derivatives
11/08/2001	WO2001083454A1 Benzosuberonylpiperidine compounds as analgesics
11/08/2001	WO2001083452A1 Novel tricyclic compounds
11/08/2001	WO2001083450A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001	WO2001083445A1 Biphenyl butyric acid derivative as a matrix metalloproteinase inhibitor
11/08/2001	WO2001083440A2 Synthesis and use of thienotriazolodiazepines
11/08/2001	WO2001083439A2 Novel $g(y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
11/08/2001	WO2001083438A2 New gamma selective retinoids
11/08/2001	WO2001083436A2 Small technetium-99m and rhenium labeled agents and methods for imaging tumors
11/08/2001	WO2001083434A2 P-(sulfonyl)-aryl and heteroaryls amines
11/08/2001	WO2001083427A1 PPARη MODULATORS
11/08/2001	WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	WO2001083093A1 Process and device for producing liquid dosage formulations
11/08/2001	WO2001083031A2 Topical composition for the treatment of psoriasis and related skin disorders
11/08/2001	WO2001083020A1 Antineoplastic platinum therapeutic method and composition
11/08/2001	WO2001082980A1 A medicinal aerosol formulation
11/08/2001	WO2001082969A2 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
11/08/2001	WO2001082967A1 MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION
11/08/2001	WO2001082966A1 Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
11/08/2001	WO2001082965A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	WO2001082956A1 Pharmaceutical composition
11/08/2001	WO2001082949A2 Method of reducing side effects of chemotherapy in cancer patients
11/08/2001	WO2001082948A2 Uses of tgap7 for the modulation of leucocyte activation
11/08/2001	WO2001082938A2 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate
11/08/2001	WO2001082937A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
11/08/2001	WO2001082936A1 Use of fucoidin in the treatment of arthritis
11/08/2001	WO2001082935A1 Remedies for cancer
11/08/2001	WO2001082934A1 Intraperitoneal administration of adenosine for the treatment or prevention of gastrointestinal or systemic diseases
11/08/2001	WO2001082933A2 Compositions and methods for stabilizing modified tissue
11/08/2001	WO2001082932A2 Methods and compositions for enhancing cellular function through protection of tissue components
11/08/2001	WO2001082931A1 (+) naloxone and epinephrine combination therapy
11/08/2001	WO2001082930A1 Pyrazole antimicrobial agents
11/08/2001	WO2001082929A2 Epichatechin as no-synthase inhibitor and uses
11/08/2001	WO2001082928A1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
11/08/2001	WO2001082927A1 Antibiral compositions containing phorbol derivatives as the main active ingredient
11/08/2001	WO2001082926A1 Manipulation of oxidative phosphorylation for hypersensitizing tumor cells to glycolytic inhibitors
11/08/2001	WO2001082924A1 Phosphate transport inhibitors
11/08/2001	WO2001082923A1 Estrogen receptor modulators
11/08/2001	WO2001082922A1 Oral compositions comprising polyphenol herbal extracts
11/08/2001	WO2001082921A2 Use of d-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression
11/08/2001	WO2001082920A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
11/08/2001	WO2001082919A2 Methods of and compounds for inhibiting calpains
11/08/2001	WO2001082918A2 Method for the prevention of apoptosis
11/08/2001	WO2001082917A2 Treatment of hypertriglyceridemia and other conditions using lxr modulators
11/08/2001	WO2001082916A2 Combination therapeutic compositions and methods of use
11/08/2001	WO2001082914A2 Topical anesthetic/opioid formulations and uses thereof
11/08/2001	WO2001082913A2 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
11/08/2001	WO2001082912A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE
11/08/2001	WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001	WO2001082910A2 Combination of progesterone and mifepristone for cancer therapy
11/08/2001	WO2001082908A2 Ginsenoside chemotherapy
11/08/2001	WO2001082907A2 Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
11/08/2001	WO2001082906A1 Powders for use in a dry powder inhaler
11/08/2001	WO2001082905A1 Pharmaceutical formulation comprising carrier beads coated with a layer of valaciclovir
11/08/2001	WO2001082904A1 A core formulation
11/08/2001	WO2001082903A1 Enteric coated formulation of bisphosphonic acid compounds and associated therapeutic methods
11/08/2001	WO2001082902A1 Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane
11/08/2001	WO2001082900A1 Non-invasive gene targeting to the brain
11/08/2001	WO2001082897A2 Liposome drug delivery
11/08/2001	WO2001082896A1 Hemostatic agent, method and carrier for applying a blood clotting agent
11/08/2001	WO2001082895A2 Guaifenesin sustained release formulation and tablets
11/08/2001	WO2001082888A1 Lipochroman-6 as no-synthase inhibitor and uses
11/08/2001	WO2001082885A1 Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa
11/08/2001	WO2001082878A1 Treatment of skin damage using acetyl carnitine and phosphatidylcholine and/or ascorbyl fatty acid esters
11/08/2001	WO2001082875A2 A core formulation
11/08/2001	WO2001082874A2 A medicinal aerosol formulation
11/08/2001	WO2001082873A2 A medicinal aerosol formulation
11/08/2001	WO2001082872A2 A medicinal aerosol formulation
11/08/2001	WO2001082868A2 A medicinal aerosol formulation
11/08/2001	WO2001082867A2 A core formulation
11/08/2001	WO2001082863A2 Polyacid/polyalkylene oxide foams and gels and methods for their delivery
11/08/2001	WO2001082861A2 Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters
11/08/2001	WO2001082860A2 Use of ursodeoxycholic acid for potentiation of the phototoxic effect of photodynamic therapy
11/08/2001	WO2001082859A2 Method for producing r-teatrol analogs having an antineoplastic activity
11/08/2001	WO2001082780A2 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents
11/08/2001	WO2001082720A1 Pet food composition for reducing inflammatory response in cats
11/08/2001	WO2001068070A8 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2001049657A8 2-`3-amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors
11/08/2001	WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001040195A3 Control of arthropods in animals
11/08/2001	WO2001040180A3 N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001038331A3 Pyrazolo[1,5-d][1,2,4]triazines for enhancing cognition
11/08/2001	WO2001034617A3 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
11/08/2001	WO2001034183A3 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
11/08/2001	WO2001034180A3 Interferon gamma for the treatment of asthma
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001032128A3 Human chemokine beta-13
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001026651A3 Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
11/08/2001	WO2001018035A3 Muc-1 derived peptides

1 ... 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 5989 5990 5991 ... 7860